Efficacy of esomeprazole for resolution of symptoms of heartburn and acid regurgitation in continuous users of non-steroidal anti-inflammatory drugs
dc.contributor.author | Hawkey, C. J. | en_US |
dc.contributor.author | Jones, R. H. | en_US |
dc.contributor.author | Yeomans, N. D. | en_US |
dc.contributor.author | Scheiman, James M. | en_US |
dc.contributor.author | Talley, Nicholas J. | en_US |
dc.contributor.author | Goldstein, J. L. | en_US |
dc.contributor.author | Ahlbom, H. | en_US |
dc.contributor.author | Næ;sdal, J. | en_US |
dc.date.accessioned | 2010-06-01T20:34:01Z | |
dc.date.available | 2010-06-01T20:34:01Z | |
dc.date.issued | 2007-04 | en_US |
dc.identifier.citation | HAWKEY, C. J.; JONES, R. H.; YEOMANS, N. D.; SCHEIMAN, J. M.; TALLEY, N. J.; GOLDSTEIN, J. L.; AHLBOM, H.; NÆ;SDAL, J. (2007). "Efficacy of esomeprazole for resolution of symptoms of heartburn and acid regurgitation in continuous users of non-steroidal anti-inflammatory drugs." Alimentary Pharmacology & Therapeutics 25(7): 813-821. <http://hdl.handle.net/2027.42/73675> | en_US |
dc.identifier.issn | 0269-2813 | en_US |
dc.identifier.issn | 1365-2036 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/73675 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=17373920&dopt=citation | en_US |
dc.format.extent | 581515 bytes | |
dc.format.extent | 3109 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Blackwell Publishing Ltd | en_US |
dc.rights | 2007 The Authors Journal compilation 2007 Blackwell Publishing Ltd | en_US |
dc.title | Efficacy of esomeprazole for resolution of symptoms of heartburn and acid regurgitation in continuous users of non-steroidal anti-inflammatory drugs | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Otolaryngology | en_US |
dc.subject.hlbsecondlevel | Pharmacy and Pharmacology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | § Division of Gastroenterology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI | en_US |
dc.contributor.affiliationother | * Institute of Clinical Research Trials Unit, University Hospital, Nottingham | en_US |
dc.contributor.affiliationother | † GKT Department of General Practice and Primary Care, King's College London, London, UK | en_US |
dc.contributor.affiliationother | † University of Western Sydney Medical School, Sydney, Australia | en_US |
dc.contributor.affiliationother | ¶ Mayo Clinic College of Medicine, Rochester, MN | en_US |
dc.contributor.affiliationother | ** Department of Medicine, University of Illinois at Chicago, Chicago, IL, USA | en_US |
dc.contributor.affiliationother | †† AstraZeneca R&D, MÖlndal, Sweden | en_US |
dc.identifier.pmid | 17373920 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/73675/1/j.1365-2036.2006.03210.x.pdf | |
dc.identifier.doi | 10.1111/j.1365-2036.2006.03210.x | en_US |
dc.identifier.source | Alimentary Pharmacology & Therapeutics | en_US |
dc.identifier.citedreference | McCarthy D. Nonsteroidal anti-inflammatory drug-related gastrointestinal toxicity: definitions and epidemiology. Am J Med 1998; 105: 3S – 9S. | en_US |
dc.identifier.citedreference | Cullen DJ, Seager JM, Holmes S, et al. Pharmacoepidemiology of non-steroidal anti-inflammatory drug use in Nottingham general practices. Aliment Pharmacol Ther 2000; 14: 177 – 85. | en_US |
dc.identifier.citedreference | Voutilainen M, Sipponen P, Mecklin JP, Juhola M, Farkkila M. Gastroesophageal reflux disease: prevalence, clinical, endoscopic and histopathological findings in 1128 consecutive patients referred for endoscopy due to dyspeptic and reflux symptoms. Digestion 2000; 61: 6 – 13. | en_US |
dc.identifier.citedreference | Wolfe F, Hawley DJ. The comparative risk and predictors of adverse gastrointestinal events in rheumatoid arthritis and osteoarthritis: a prospective 13 year study of 2131 patients. J Rheumatol 2000; 27: 1668 – 73. | en_US |
dc.identifier.citedreference | Kotzan J, Wade W, Yu HH. Assessing NSAID prescription use as a predisposing factor for gastroesophageal reflux disease in a Medicaid population. Pharm Res 2001; 18: 1367 – 72. | en_US |
dc.identifier.citedreference | Laine L. The gastrointestinal effects of nonselective NSAIDs and COX-2-selective inhibitors. Semin Arthritis Rheum 2002; 32 ( 3 Suppl. 1 ): 25 – 32. | en_US |
dc.identifier.citedreference | Langman MJ, Jensen DM, Watson DJ, et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA 1999; 282: 1929 – 33. | en_US |
dc.identifier.citedreference | Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib long-term arthritis safety study. JAMA 2000; 282: 1247 – 55. | en_US |
dc.identifier.citedreference | Lisse JE, Perlman M, Johannson G, et al. Gastrointestinal tolerability and effectiveness of rofecoxib vs. naproxen in the treatment of osteoarthritis: a randomized, controlled trial. Ann Inter Med 2003; 139: 539 – 46. | en_US |
dc.identifier.citedreference | Veldhuyzen van Zanten SJO, Bradette M, Chiba N, et al. Evidence-based recommendations for short- and long-term management of uninvestigated dyspepsia in primary care: an update of the Canadian Dyspepsia Working Group (CanDys) clinical management tool. Can J Gastroenterol 2005; 19: 285 – 303. | en_US |
dc.identifier.citedreference | Singh G, Rosen Ramey D. NSAID induced gastrointestinal complications: the ARAMIS perspective-1997. Arthritis, Rheumatism, and Aging Medical Information System. J Rheumatol Suppl 1998; 25 ( Suppl. 51 ): 8 – 16. | en_US |
dc.identifier.citedreference | Elliot SL, Ferris RJ, Giraud AS, et al. Indomethacin damage to rat gastric mucosa is markedly dependent on luminal pH. Clin Exp Pharmacol Physiol 1996; 23: 432 – 4. | en_US |
dc.identifier.citedreference | McCarthy DM. Prevention and treatment of gastrointestinal symptoms and complications due to NSAIDs. Best Pract Clin Gastroenterol 2001; 15: 755 – 73. | en_US |
dc.identifier.citedreference | Ekstrom P, Carling L, Wetterhus S, et al. Prevention of peptic ulcer and dyspeptic symptoms with omeprazole in patients receiving continuous non-steroidal anti-inflammatory drug therapy. A Nordic multicentre study. Scand J Gastroenterol 1996; 31: 753 – 8. | en_US |
dc.identifier.citedreference | Yeomans N, Wilson I, Langstrom G, et al. Quality of life in chronic NSAID users: a comparison of the effect of omeprazole and misoprostol. Scand J Rheumatol 2001; 30: 328 – 34. | en_US |
dc.identifier.citedreference | Hawkey C, Talley NJ, Yeomans ND, et al. Improvements with esomeprazole in patients with upper gastrointestinal symptoms taking non-steroidal antiinflammatory drugs, including selective COX-2 inhibitors. Am J Gastroenterol 2005; 100: 1028 – 36. | en_US |
dc.identifier.citedreference | Scheiman JM, Yeomans ND, Talley NJ, et al. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. Am J Gastroenterol 2006; 101: 701 – 10. | en_US |
dc.identifier.citedreference | Goldstein JL, Johansen JF, Suchower LJ, Brown KA. Healing of gastric ulcers with esomeprazole vs. ranitidine in patients who continued to receive NSAID therapy: a randomized trial. Am J Gastroenterol 2005; 100: 2650 – 7. | en_US |
dc.identifier.citedreference | Junghard O, Lauritsen K, Talley NJ, et al. Validation of seven graded diary cards for severity of dyspeptic symptoms in patients with non-ulcer dyspepsia. Eur J Surg Suppl 1998; 583: 106 – 11. | en_US |
dc.identifier.citedreference | Junghard O, Wiklund I. Validation of a 4-graded scale for severity of heartburn in symptomatic GERD patients [abstract]. Gut 2004; 53 ( Suppl. VI ): A103. | en_US |
dc.identifier.citedreference | Hirschowitz BI. Nonsteroidal antiinflammatory drugs and the gastrointestinal tract. Gastroenterologist 1994; 2: 207 – 23. | en_US |
dc.identifier.citedreference | Tenenbaum J. The epidemiology of nonsteroidal anti-inflammatory drugs. Can J Gastroenterol 1999; 13: 119 – 22. | en_US |
dc.identifier.citedreference | Johnson DA, Fennerty MB. Heartburn severity underestimates erosive esophagitis severity in elderly patients with gastroesophageal reflux disease. Gastroenterology 2004; 126: 660 – 4. | en_US |
dc.identifier.citedreference | Allen A, Flemstrom G, Garner A, Kivilaakso E. Gastroduodenal mucosal protection. Physiol Rev 1993; 73: 823 – 57. | en_US |
dc.identifier.citedreference | Rich M, Scheiman JM. Nonsteroidal anti-inflammatory drug gastropathy at the new millennium: mechanisms and prevention. Semin Arthritis Rheum 2000; 30: 167 – 79. | en_US |
dc.identifier.citedreference | Levine RA, Schwartzel EH. Effect of indomethacin on basal and histamine-stimulated human gastric acid secretion. Gut 1984; 25: 718 – 22. | en_US |
dc.identifier.citedreference | Savarino V, Mela GS, Zentilin P, et al. Effect of one-month treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) on gastric pH of rheumatoid arthritis patients. Dig Dis Sci 1998; 43: 459 – 63. | en_US |
dc.identifier.citedreference | Kulkarni SG, Parikh SS, Shankhpal PD, et al. Gastric emptying of solids in long-term NSAID users: correlation with endoscopic findings and Helicobacter pylori status. Am J Gastroenterol 1999; 94: 382 – 6. | en_US |
dc.identifier.citedreference | Bouras EP, Burton DD, Camilleri M, Stephens DA, Thomforde GM. Effect of cyclooxygenase inhibitors on gastric emptying and small intestinal transit in humans. Neurogastroenterol Motil 2004; 16: 729 – 35. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.